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Pharmacopuncture is a new needle therapy that integrates acupuncture and herbal therapies, and it has the potential to treat many
diseases. A systematic review was performed to summarize and critically evaluate clinical trial evidence regarding the eﬀectiveness
of pharmacopuncture for asthma. Eight electronic databases and six journals were searched in this study. Randomized clinical
trials (RCTs) in which human patients with asthma were treated with pharmacopuncture were included. The selection of studies,
data extraction, and validation were performed independently by two reviewers. Four RCTs met our inclusion criteria, and the
evidence from all RCTs in this study was positive. The meta-analysis showed statistically signiﬁcant eﬀects of pharmacopuncture
compared to conventional treatment (n = 341, Risk Ratio = 1.13, 95% CI of 1.05 to 1.23, P = .002, heterogeneity: χ2 = 3.55,
P = .31, I2 = 16%). Two trials showed favorable eﬀects of pharmacopuncture on peak expiratory ﬂow (PEF). However, few
rigorous trials have tested the eﬀects of pharmacopuncture on asthma. The results of our systematic review point to the potential
beneﬁts of pharmacopuncture for adults with asthma, and we suggest further RCTs and the development of a standard method of
pharmacopuncture therapy.
1.Introduction
Asthma is a worldwide problem with an estimated 300
million aﬀected individuals. The World Health Organization
(WHO) has estimated that 15 million disability-adjusted life
years are lost annually due to asthma, representing 1% of
the total global disease burden. Annual worldwide deaths
from asthma have been estimated at 250,000, and mortality
does not appear to correlate with prevalence [1]. Asthma is
a chronic inﬂammatory disorder of the airways. Although
therearemanyallopathictreatments,includingbronchodila-
tors and corticosteroids, which either focus on long-term
controlorimmediaterelief,thereisnosinglemedicationthat
is eﬀective against both the inﬂammatory and bronchocon-
strictive components of asthma. Therefore, many suﬀerers
turn to alternative or complementary therapies, typically in
conjunction with their conventional medications [2].
Pharmacopuncture, or herbal acupuncture (integrated
acupuncture and herb therapies), is one of the new acupunc-
turetherapieswidelyusedintraditionalEastAsianmedicine.
An herbal extract is injected into acupuncture points to
cure certain diseases [3]. Pharmacopuncture is much more
eﬀective than acupuncture alone, and its eﬀects vary with the
herbs used [4, 5]. This type of therapy is similar to acupoint
injection therapy or aqua acupuncture in traditional Chinese
medicine (TCM). However, acupoint injection therapy uses
herbs, medicines, self-blood, oxygen, and allergens [4]. The
indications for pharmacopuncture are diverse [3], and the
clinical usefulness of herbal acupuncture is especially good
in disorders of the musculoskeletal system [6]. Choi et al.
suggested that hominis placenta extract (HPE) pharmacop-
uncture is eﬀective for allergic diseases, including asthma,
and autoimmune diseases. However, this study was not able
to investigate the speciﬁc eﬀect of HPE pharmacopuncture
on asthma [7]. As there is no other systematic study of
pharmacopuncture as an asthma treatment, the aim of
this systematic review was to summarize and critically
evaluate clinical trial evidence regarding the eﬀectiveness of
pharmacopuncture for asthma.
2. Methods
2.1. Data Sources. The following electronic databases were
searched from inception to November 2009: PubMed,2 Evidence-Based Complementary and Alternative Medicine
CINAHL,Medline,CochranLibrary,threeKoreanDatabases
(KoreaMed, KISS, and DBPIA), and one Chinese Medical
Database (CNKI). The ﬁrst search term was “asthma”, and
the second term was “pharmacopuncture”, “herbal acupunc-
ture”, “acupoint”, “acupuncture point”, “aqua acupuncture”,
or “aquapuncture”. The third search term was “injection” or
“infusion”. We combined these three terms for the electronic
search. Corresponding Korean or Chinese terms were also
used. In addition, we manually searched the following
Korean journals from inception to November 2009: The
Korean J. Meridian and Acupoint, J. Pharmacopuncture
Institute, The Korean J. Acupuncture and Moxibution Soci-
ety, Korean J. Orient Int. Med, J. Korean Oriental Med,
and J. Korean Orient Pediatrics. References were addressed
in the original articles, and reviews were further searched
for relevant studies. Dissertations and abstracts were also
included.
2.2. Study Selection. All randomized controlled trials (RCTs)
in which human patients with asthma were treated
with pharmacopuncture or herbal acupoint injection were
included. Studies that incorporated other diseases were
excluded.Trialsusingotherinjections,suchaslocalanesthet-
ics,steroids,oxygen,allergens,andself-blood,wereexcluded.
Trials in which pharmacopuncture therapies were combined
with other therapies were excluded. However, trials that had
the same concomitant treatments in the conventional group
and the control group or had pharmacopuncture therapy
in addition to the control group therapy were included.
Also, studies using interventions of unproven eﬃcacy in the
control group were excluded.
2.3. Data Extraction and Quality Assessment. Hard copies of
all articles were obtained and read in full. All articles were
read by two independent reviewers (F. Y. Shen and M. S.
Lee), and data from the articles were validated and extracted
according to predeﬁned criteria (Table 1). Risk of bias was
assessed using the Cochrane classiﬁcation for the following
four criteria: sequence generation, blinding, incomplete
outcome measures, and allocation concealment [8]. As it is
very hard to blind therapists to the use of pharmacopuncture
therapy, we assessed patient and assessor blinding separately.
Disagreements were resolved by discussion between the
two reviewers (F. Y. Shen and M. S. Lee). There were no
disagreements between the reviewers about risk of biases.
2.4. Data Synthesis. To summarize the eﬀects of pharmacop-
uncture on outcomes, we used the Cochrane Collaboration’s
RevMan software for Windows (Version 5.0, Review Man-
ager,RevMan;Copenhagen:TheNordicCochraneCentre)to
abstract the risk estimates (relative risk: RR). Weighted mean
diﬀerences(WMDs),standard meandiﬀerences (SMDs)and
the 95% conﬁdence interval (CI) were also calculated for
continuous data. For studies with insuﬃcient information,
we contacted the primary authors to acquire and verify data
when possible. As suggested by the Cochrane Collaboration’s
software, the variance was input using a correlation factor
of 0.5 [9]. If appropriate, we then pooled the data across
studies using random eﬀects models if excessive statistical
heterogeneitydidnotexist.Thechi-squaretest,tau2 test,and
the Higgins I2 test were used to assess heterogeneity.
3. Results
3.1. Study Description. The literature searches revealed 660
articles, of which 656 studies were excluded (Figure 1). Four
RCTs met our inclusion criteria, and their key data are listed
in Table 1.A l lR C T s[ 10–13] originated from China, and all
trials adopted a two-armed parallel group design. Together,
they included a total of 385 patients. The patients were
all adults, and the duration of disease ranged from 0.5–49
years. All levels of asthma severity were represented in the
patients. One study analyzed patients during catabasis [12],
andtherest[10,11,13]includedpatientswithexacerbations.
Duration of treatment in one trial was two years [12], and
other trials [10, 11, 13] ranged from 10–15 days. There were
two trials that used single-herb pharmacopuncture [10, 12].
The others used herbal formula compounds [11, 13]. Radix
Astragaliwasusedastheingredientofinjectioninthreetrials
[10–12]. The acupoints selected in the studies were those
commonly used for asthma therapy based on TCM theory,
and the following two acupoints overlapped: BL13 in three
trials [10, 12, 13] and RN22 in two trials [11, 13]. One trial
[11] used a single acupoint, and the other trials [10, 12, 13]
used several points.
3.2. Study Quality. All of the included RCTs had a high risk
of bias. They did not report methods of sequence generation,
incomplete outcome measures, or allocation concealment.
3.3. Outcomes. Wangand Fu [10] tested the eﬀect of phar-
macopuncturetherapyinadditiontoinhalationtherapy.The
symptom response rate in the combined therapy group was
91.4% whereas the rate was 76.3% in the inhalation-only
treated group (P<. 01). The forced vital capacities (FVCs)
for the combined group and the treated group were 3.18
± 0.88L and 2.70 ± 0.76L (P<. 01), respectively. Also,
the forced expiratory volumes in 1 second (FEV1) for the
combined group and the treated group were 2.08 ± 0.69L
and 1.77 ± 0.85L (P<. 01), respectively. Finally, the peak
expiratory ﬂows (PEFs) for the combined group and the
treated group were 3.02 ± 0.97L/sec and 2.66 ± 0.73L/sec
(P<. 01), respectively.
Lu and Tang [11] tested the eﬀect of pharmacopuncture
therapy in addition to conventional asthma therapies. The
symptom response rate in the conventional plus pharmacop-
uncture therapy group was 97.1% whereas it was 76.5% in
the control group (P<. 05).
Liang et al. [12] also tested the eﬀects of pharmacopunc-
ture therapy in addition to conventional asthma therapies.
The symptom response rate in the pharmacopuncture
therapy group was 97.14% whereas the rate was 88.57% in
the control group (P<. 01). The diﬀerence between post-
treatment and prior-treatment of FVC in the combination
therapy group were 2.38 ± 0.52L versus 0.21 ± 0.50L
(P<. 01) for the control group. The diﬀerence betweenEvidence-Based Complementary and Alternative Medicine 3
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.4 Evidence-Based Complementary and Alternative Medicine
Publications identiﬁed (n = 660)
Publications excluded by screening the title and
abstract (n = 361)
￿ Duplicated studies (n = 24)
￿ Not relevant to asthma or incorporated other diseases
(n = 92)
￿ Not relevant to pharmacopuncture or acupoint
injection (n = 92)
￿ Not a clinical trial (n = 153)
Articles further evaluated by full text (n = 299)
Publications excluded after reading the full text
(n = 295)
￿ Not herbal injections or mixed with other injections
(n = 258)
￿ Uncontrolled trials, case report or case series
(n = 25)
￿ Non-randomized controlled trials (n = 4)
￿ RCTs excluded (n = 8) for the following reasons;
RCTs included (n = 4)
-P a r to fam i x e di n t e r v e n t i o n( n = 5)
- Compared with unproven therapies (n = 3)
Figure 1: Flowchart of trial selection process. RCT: randomized clinical trial.
post-treatment and prior-treatment values of FEV1 in the
combination therapy group were 1.67 ± 0.58L versus 0.64
± 0.60L (P<. 01) for the control group.
Tong [13] compared the eﬀects of pharmacopuncture
therapy and inhalation therapy in addition to conventional
therapy. The symptom response rate in the pharmacop-
uncture therapy group was 95% whereas the rate was 90%
in the inhalation therapy group (P>. 05). PEFs for
the pharmacopuncture and inhalation therapy groups were
360.98 ± 73.03L/min and 346.96 ± 70.48L/min (P<. 05),
respectively.
3.4. Response Rate. A l lR C T s[ 10–13]c o m p a r e dp h a r m a -
copuncture with conventional treatment. The meta-analysis
showed statistically signiﬁcant eﬀects of pharmacopuncture
compared with conventional treatment (n = 341, RR = 1.13,
95% CI of 1.05 to 1.23, P = .002, heterogeneity: χ2 = 3.55,
P = .31, I2 = 16%, Figure 2(a)). Subgroup analyses also
showed beneﬁcial eﬀects of conventional treatment drugs
plus pharmacopuncture as compared with conventional
treatments alone (n = 257, RR = 1.17; 95% CI of 1.07 to
1.27, P = .002, heterogeneity: χ2 = 1.85, P = .40, I2 = 0%,
Figure 2(a)).
3.5. Ventilation. Two RCTs [10, 12] compared the eﬀects
of conventional treatments plus pharmacopuncture and
conventional treatments alone on FVC and FEV1. These
two RCTs reported that FVC signiﬁcantly improved with
conventional treatments plus pharmacopuncture. The extent
of statistical heterogeneity prevented a meaningful meta-
analysis of the two trials (n = 228, WMD = 0.71; 95%
CI of 0.26 to 1.16, P = .002, heterogeneity: χ2 = 6.15,
P = .002, I2 = 84%, Figure 2(b)). These two RCTs also
reported that conventional treatments plus pharmacopunc-
ture signiﬁcantly improved FEV1 as compared with conven-
tional treatments alone. However, the meta-analysis of these
two RCTs failed to show favorable eﬀects of conventional
treatments plus pharmacopuncture on FEV1 compared withEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Forest plot of pharmacopuncture for asthma symptoms. (a) Response rate; (b) FVC; (c)FEV1; (d) PEF. FVC: forced vital capacity;
FEV1: forced expiratory volume in 1 second; PEF: peak expiratory ﬂow; PA: pharmacopuncture; Cont: control.6 Evidence-Based Complementary and Alternative Medicine
conventional treatments alone (n = 228, WMD = 0.98; 95%
CI of −0.33 to 2.29, P = .14). Marked heterogeneity was
observed in this model (χ2 = 53.49, P<. 00001, I2 = 98%,
Figure 2(c)).
Two RCTs [10, 13] tested conventional treatments plus
pharmacopuncture compared with conventional treatments
alone on PEF. One RCT reported beneﬁcial eﬀects of
pharmacopuncture on PEF whereas the other RCT failed
to show any beneﬁts. However, the meta-analysis showed
favorable eﬀects of pharmacopuncture on PEF (n = 248,
WMD = 0.34; 95% CI of 0.08 to 0.59, P = .01, heterogeneity:
χ2 = .64, P = .42, I2 = 0%, Figure 2(d)).
4. Discussion
The evidence from all RCTs in this study was positive.
However, few rigorous trials have tested the eﬀects of
pharmacopuncture on asthma. Furthermore, the number of
trials and the total sample size are too small to draw any ﬁrm
conclusions. Overall, our ﬁndings suggested the eﬀectiveness
of pharmacopuncture for asthma.
All of the RCTs had high risk of bias. Speciﬁcally,
although randomization was mentioned, the details of
the randomizing methods were not clear. None of the
RCTs reported dropout, blinding, or allocation concealment.
Although most of the RCTs had positive results, these low-
quality trials are more likely to overestimate the size of the
eﬀect [14]. Such low quality trials are the main barrier to
making a ﬁrm conclusion. Moreover, all of the RCTs in
this study were conducted in China, a country that rarely
publishes negative results [15]. These limitations may lead
to the positive results in this study.
Another limitation is the design of some of these RCTs.
There are three RCTs [10–12]d e s i g n e da sA+Bv e r s u sB .
Duetotheirdesignfeatures,theywerepronetofalse-positive
results. The eﬀects of these speciﬁc therapies are unable to
be demonstrated in these RCTs [16]. The remaining RCT
[13] showed signiﬁcant eﬀects of pharmacopuncture on
asthma in comparison to inhalation therapy. However, both
the intervention group and the control group concurrently
received conventional therapy. All RCTs analyzed symptom
response rate as a subjective outcome, but the details
of symptom response rate were not uniﬁed. Importantly,
FEV1, FVC, and PEF measurements have gained widespread
acceptance for use in asthma patients over 5 years of age
[17]. However, contrary to the symptom response rate, such
objective measurements were reported in only a minority
of trials. Another uncertain factor is that the selection
of the acupoints and herbs was not consistent among
trials.
According to the meta-analyses, we found signiﬁcant
eﬀects of pharmacopuncture on response rate as compared
with conventional treatment. The extent of statistical het-
erogeneity prevented a meaningful meta-analysis of the two
trials [10, 12] that compared the eﬀects of pharmacopunc-
tureplusconventionaltreatmentsonFVC.Twotrials[10,13]
showed favorable eﬀects of pharmacopuncture on PEF.
From our results, we cannot prove that the speciﬁc
therapeutic eﬀects of pharmacopuncture on asthma are
due to their design features, but we found that pharma-
copuncture can improve the eﬀectiveness of conventional
treatments as an adjunctive therapy. Furthermore, we found
300 clinical studies of acupoint injection therapy for asthma,
and 91 used herbs or herb mixtures along with other
injections. This ﬁnding indicates that acupoint injection
therapy is widely used for asthma and is also becoming
an important therapy with herbal acupoint injection or
pharmacopuncture. To be classiﬁed as a complementary and
alternative medicine, pharmacopuncture as well as other
alternative or complementary therapies was used mostly in
conjunction with allopathic medications [18, 19].
From the usage of pharmacopuncture in the clinic, we
can deduce that this kind of therapy would have some eﬀects
on asthma, especially as an adjunctive therapy. However, we
cannot make a ﬁrm conclusion. Therefore, the purpose of
this paper was to guide future standardized studies so that
they can provide conclusive evidence for the eﬀectiveness of
pharmacopuncture on asthma. Future studies should follow
RCT methods. Second, a speciﬁc trial design has to be
developed. For example, the intervention group should use
pharmacopuncture therapy alone and interventions used in
the other group should have proven eﬃcacy. Third, a uniﬁed
measurement should be developed. Fourth, a standard herb
and acupoint selection must be developed. From our results,
we discovered that the herb and acupoint most commonly
used for treating asthma were Radix Astragali and BL13,
respectively. Results of these future studies should provide
useful data for developing a standard pharmacopuncture
therapy for asthma.
In summary, there were many limitations precluding a
ﬁrm conclusion on the eﬀectiveness of pharmacopuncture in
asthma suﬀerers. Despite this, we attempted to clearly sort
our data to investigate the possibility of a pharmacopuncture
treatment for asthma. However, we cannot be absolutely cer-
tainthatoursearcheslocatedallrelevantRCTs.Furthermore,
we also conducted meta-analyses that can increase power,
improve precision, answer questions not posed by individual
studies, settle controversies arising from conﬂicting results,
and generate new hypotheses [8]. However, the use of
statistics does not guarantee that the results are valid. In our
case, conclusions must remain tentative.
5. Conclusion
Our systematic review shows the potential beneﬁt of
pharmacopuncture for adults with asthma, both in acute
exacerbation and catabasis. However, the total number of
RCTsincludedintheanalysisandthemethodologicalquality
were too low to draw any ﬁrm conclusions. More RCTs
are needed, and a standard method of pharmacopuncture
therapy for asthma should be developed.
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